Related by context. All words. (Click for frequent words.) 75 plus methotrexate 70 achieved ACR# 69 oxycodone CR 69 8mg/kg 69 ACR# responses 68 mcg BID 68 lumbar spine BMD 68 log# IU mL 67 adalimumab 67 mg BID 67 CIMZIA TM 67 HAQ DI 67 receiving golimumab 66 methotrexate monotherapy 66 MADRS score 66 mg QD 66 PASI scores 66 #mg/day [002] 65 dapagliflozin plus 65 tapentadol ER 65 placebo p = 65 #mg BID [003] 65 mcg QD 65 #mg BID [001] 65 placebo dexamethasone 65 infliximab monotherapy 65 certolizumab 65 ACR# ACR# 65 R# #mg BID 65 achieved CCyR 65 CCyR 65 mitoxantrone plus 65 4mg/kg 65 morphometric vertebral fractures 65 placebo p 65 q#h 64 ACR# response 64 ACTEMRA TM 64 progression TTP 64 fasting plasma glucose FPG 64 neurologic progression 64 relapsed MM 64 mg ustekinumab 64 plus prednisone prednisolone 64 HBeAg seroconversion 64 radiographic progression 64 Free Survival PFS 64 somatostatin analog 64 VELCADE melphalan 64 Q2W 64 annualized relapse 64 TEAEs 64 #mg QD [002] 64 Flu Cy 63 FOLFIRI 63 peginterferon alfa 2a 63 complete cytogenetic response 63 mTSS 63 ATACAND 63 tolterodine ER 63 adalimumab Humira 63 prednisone prednisolone plus 63 achieved statistical significance 63 baseline HbA1c 63 RLAI 63 achieved PASI 63 lopinavir r arm 63 abacavir lamivudine 63 clinically meaningful improvements 63 plus prednisone 63 desvenlafaxine succinate 63 adefovir 63 -#.# mg dL [001] 63 tipranavir r 63 plus OBT 63 QTcF 63 peginterferon alfa 2b 62 AGILECT R 62 paliperidone ER 62 FOLPI 62 plus dexamethasone 62 ORENCIA 62 FOLFOX4 62 irbesartan 62 plasma HCV RNA 62 alfa 2a 62 #.#/#.# mmHg [001] 62 sustained virological response 62 clinically meaningful improvement 62 definite stent thrombosis 62 liver histology 62 tocilizumab 62 RoACTEMRA 62 CIMZIA ™ 62 EDSS scores 62 lopinavir r 62 tirofiban 62 APTIVUS r 62 mg TID 62 BARACLUDE ® 62 mg kg belimumab 62 PegIFN RBV 62 virologic response 62 glimepiride 61 ALT flares 61 #mg/m# [001] 61 adjunctive placebo 61 log# copies mL 61 radiotherapy RT 61 sUA 61 solifenacin 61 dalteparin 61 p = NS 61 budesonide pMDI 61 bortezomib refractory 61 venlafaxine XR 61 serum phosphorus 61 laboratory abnormalities 61 moderate renal impairment 61 -#.# mg dL [002] 61 FluCAM 61 mg kg dose 61 ritonavir boosted atazanavir 61 carboplatin paclitaxel 61 virological response 61 FOLFOX6 61 azilsartan medoxomil 61 DAS# remission 61 MCyR 61 CIMZIA TM certolizumab pegol 61 virologic failure 61 estramustine 61 timepoints 61 neutropenia dehydration dyspnea 61 Doxil ® 61 HAM D# scores 61 ribavirin RBV 61 plus ribavirin 61 rosuvastatin #mg 61 Pegasys ® 61 #.#mg/dL 61 binary restenosis 61 Peg IFN 61 REYATAZ r arm 61 cytogenetic response 61 Psoriasis Area 61 anthracycline taxane 61 interferon ribavirin 61 #mg/day [001] 61 Pharmacokinetic parameters 61 median PFS 61 CR nPR 61 humanized interleukin 6 61 mcg albinterferon alfa 2b 61 adefovir treated 61 biologic DMARD 61 ACR# [002] 60 saline placebo 60 chlorambucil 60 ribavirin therapy 60 cisplatin vinorelbine 60 RRMS patients 60 methotrexate MTX 60 bleeding pallor 60 Median PFS 60 ACE inhibitor ramipril 60 CR CRu 60 titrated glipizide plus 60 Castration Resistant Prostate Cancer 60 interferon alfa 2a 60 PSADT 60 complete cytogenetic 60 Montgomery Asberg Depression 60 discontinuations due 60 FOLFIRI alone 60 demonstrated clinically meaningful 60 placebo PBO 60 Aptivus ® 60 mcg Albuferon 60 #mg dose [002] 60 tamsulosin 60 Scale EDSS 60 plus gemcitabine 60 adjunctive ABILIFY 60 doxazosin 60 overt nephropathy 60 seropositive patients 60 COPAXONE R 60 IIIa inhibitor 60 Zometa hazard 60 interferon beta therapy 60 pegylated interferon peg IFN 60 nonvertebral fractures 60 dose cytarabine 60 HbA 1c levels 60 Index CDAI 60 tenofovir emtricitabine 60 FOLFOX 60 ACEI ARB 60 Crohn Disease Activity 60 unresectable HCC 60 PEG IFN 60 gout flares 60 REMICADE ® 60 AZT zidovudine Retrovir 60 peg IFN 60 hour bronchodilation 60 dacarbazine DTIC 60 placebo 60 abatacept 60 receiving INTRON 60 postmenopausal osteoporotic women 60 gemcitabine carboplatin 60 clodronate 60 Expanded Disability Status 60 virological failure 60 splenectomized patients 60 ULORIC 60 incidence ≥ 60 administered subcutaneously 60 ARB telmisartan 60 DMARDs 60 salmeterol fluticasone 60 pegylated liposomal doxorubicin 60 sustained virologic response 60 lispro 60 HBeAg negative patients 60 non splenectomized 60 baminercept 60 hip BMD 60 quetiapine XR 60 TNF antagonist 60 HbA1C levels 60 ALND 60 events SAEs 60 3mg/kg 60 Secondary endpoints included 60 STELARA ® 60 ritonavir boosted 60 certolizumab pegol 60 peginterferon 60 ADCS CGIC 60 mcg kg REBETOL 59 mitoxantrone 59 Meets Primary Endpoint 59 zonisamide SR 59 APTIVUS R 59 Rating Scale MADRS 59 atazanavir ritonavir 59 KRAS mutations occur 59 TAXUS p value 59 tiotropium 59 mg/m2 IV 59 mycophenolate mofetil 59 oral hypoglycemic agent 59 dacarbazine 59 gadolinium enhancing lesions 59 extrapyramidal symptoms 59 AGILECT ® 59 log# reduction 59 ADAS cog 59 pyrexia mucositis sepsis febrile 59 IFN alfa 59 R adefovir dipivoxil 59 nadolol 59 nicardipine 59 rimonabant #mg 59 SVR# 59 oral rivaroxaban 59 Certolizumab 59 PRADAXA #mg 59 plus COPEGUS 59 IR prednisone 59 CTAP# Capsules 59 docetaxel chemotherapy 59 Thal Dex 59 #mg QD [001] 59 LPV r 59 azathioprine 59 undetectable HBV DNA 59 events TEAEs 59 serum aminotransferase levels 59 PEGINTRON TM 59 dosage regimens 59 serum phosphate levels 59 subcutaneous enoxaparin 59 CRp 59 mg qd 59 glycated hemoglobin levels 59 serum phosphate 59 mg BID dose 59 Raptiva r 59 mucosal healing 59 baseline A1C 59 evaluable subjects 59 antiretroviral naive 59 rimonabant #mg/day 59 achieved sustained virologic 59 TORISEL 59 β blockers 59 glycosylated hemoglobin levels 59 FOLFOX4 alone 59 receiving ISENTRESS 59 imatinib therapy 59 SPRYCEL ® 59 antiretroviral naïve 59 cardiovascular calcification 59 postintervention 59 oral antidiabetic medication 59 infliximab 59 angiographic outcomes 59 abdominal pain abdominal discomfort 59 fluticasone salmeterol 59 low dose cytarabine 59 P = .# 59 symptomatic VTE 59 octreotide LAR 59 comparator arm 59 % CI #.#-#.# [007] 59 statistically significant superiority 59 Ishak fibrosis score 59 folinic acid 59 hyperphenylalaninemia HPA due 59 CIMZIA R 59 Cimzia TM 59 splenectomized 59 endoscopic remission 59 prior nephrectomy 59 Oral Fingolimod 59 colesevelam HCl 59 Perforomist Inhalation Solution 59 SSRI SNRI 59 elevated transaminases 59 mcg kg 59 lumbar spine bone 59 ALVESCO 59 LVEF 59 mg p = 59 PLX STROKE targeting 59 aminotransferase elevations greater 59 nadroparin 59 Pegasys plus Copegus 59 5-FU/LV 59 KRAS mutant tumors 59 corticosteroid dose 58 R adalimumab 58 oral FTY# 58 insulin detemir 58 stage IIIb IV 58 interferon alfa 2b 58 mild renal insufficiency 58 heavily pretreated 58 -#.# log# copies mL 58 linaclotide treated 58 cisplatin chemotherapy 58 PREZISTA r arm 58 #mg doses [002] 58 HDRS 58 receiving XGEVA 58 HbA1c levels 58 BENICAR 58 severe exacerbations 58 lacosamide 58 Peginterferon 58 reduce serum phosphate 58 paclitaxel eluting stents 58 mL/min/#.# m 2 58 -#.# log# 58 ibandronate 58 DOXIL 58 corticosteroid therapy 58 p = #.# [004] 58 standard chemotherapy regimen 58 detectable HCV RNA 58 glipizide plus 58 anemia hemoglobin 58 biochemical relapse 58 valsartan 58 XGEVA 58 peginterferon alfa 2a #KD 58 fondaparinux 58 MIRAPEX 58 IPSS 58 TDF FTC 58 HBeAg positive patients 58 CrCl 58 oral allopurinol 58 LEXIVA r 58 doxorubicin cyclophosphamide 58 evaluating tivozanib 58 risedronate 58 Platelet counts 58 EBRT 58 Index CDAI score 58 #mg dose [003] 58 ARCALYST ® 58 pioglitazone HCl 58 elevated ALT 58 virologic breakthrough 58 bupropion SR 58 PsA 58 FUSILEV enhances 58 ug dose 58 pravastatin therapy 58 thromboembolic events 58 microbiological eradication 58 hematological parameters 58 dosing cohort 58 Monotherapy 58 Soliris therapy 58 clopidogrel Plavix 58 μg dose 58 mg RDEA# 58 benazepril 58 lenalidomide dexamethasone 58 NPH insulin 58 odanacatib 58 null responders 58 virologic suppression 58 angiotensin converting enzyme inhibitor 58 COPEGUS 58 prednisone prednisolone 58 infusional 5-FU/LV 58 DAS# [002] 58 experienced virologic failure 58 receiving prophylactic anticoagulation 58 mg tid 58 bezafibrate 58 undetectable HCV RNA 58 pramipexole 58 fibrinolysis 58 Folfox 58 docetaxel Injection Concentrate 58 Viread Emtriva 58 advanced hepatocellular carcinoma 58 Elitek 58 Pharmacokinetics PK 58 glycoprotein IIb IIIa inhibitor 58 FluCAM arm 58 HbA 1c 58 headache nasopharyngitis 58 DAS# scores 58 confirmed CCyR 58 EDSS score 58 placebo fluoxetine 58 baseline PASI 58 DMARD therapy 58 Acetate Rectal Suppositories 58 fosamprenavir 58 metastatic CRC 58 ARCOXIA 58 diameter stenosis 58 paricalcitol 58 lamivudine refractory patients 58 teriflunomide 58 maximal tolerated 58 DMARD 58 progressive PsA 58 mg dosed twice 58 xanthine oxidase inhibitor 58 alemtuzumab treated 58 XIENCE V PROMUS Stent 58 naïve HCV 58 #μg [002] 58 divalproex sodium 58 XIENCE V demonstrated 58 autoantibody positive 58 Abbott HUMIRA 58 patients coinfected 58 metformin sulfonylurea 58 pegylated interferon alpha 58 pulmonary exacerbations 57 recurrent VTE 57 chemoradiotherapy 57 bosentan 57 statistically significant p = 57 PEGylated anti 57 nonhematologic adverse reactions 57 TMC# r 57 piperacillin tazobactam 57 genotypic resistance 57 % CI #.#-#.# [003] 57 unfractionated heparin 57 Natalizumab 57 Secondary endpoints include 57 Secondary endpoints 57 doxorubicin docetaxel 57 clinically meaningful reductions 57 CNS LS 57 alanine aminotransferase ALT 57 active comparator 57 serologically active patients 57 pCR 57 mg simvastatin 57 locoregional recurrence 57 MACUGEN 57 Traficet EN 57 atorvastatin #mg 57 lenalidomide Revlimid R 57 cholinesterase inhibitor 57 unfractionated heparin UFH 57 ® lenalidomide 57 Fludara 57 zolmitriptan 57 partial remissions 57 BENICAR HCT 57 Mean Symptom Complex 57 R ribavirin USP 57 intravenous bolus 57 Solid Tumors criteria 57 AVODART 57 eplerenone 57 Kaplan Meier analysis 57 affective psychosis 57 visceral metastases 57 weekly subcutaneous injections 57 Lupuzor ™ 57 candesartan cilexetil 57 statistically significant efficacy 57 CC genotype 57 primary hypercholesterolemia 57 biphasic insulin aspart 57 Score TOS 57 ZOLINZA 57 recurrent genital herpes 57 aplastic anemia AA 57 KAPIDEX 57 mCi kg 57 Peginterferon alfa 2b 57 prior chemotherapy regimens 57 ARIMIDEX 57 cytogenetic responses 57 TNF inhibitor 57 mRCC 57 hypomagnesemia 57 sUA levels 57 HBeAg + 57 cyclophosphamide doxorubicin vincristine 57 QTc 57 undetectable viral load 57 #.#g/day 57 pegylated interferon 57 pegIFN 57 androgen suppression 57 MoxDuo TM IR 57 adriamycin 57 Peginterferon Alfa 2a 57 Primary endpoints 57 T2DM 57 maximal doses 57 PEG interferon 57 gemcitabine cisplatin 57 ORENCIA ® 57 perioperative complications 57 ALT elevation 57 timepoint 57 remission CR 57 Lantus ® 57 posaconazole 57 preoperative chemotherapy 57 LV dysfunction 57 Infusion Reactions Severe 57 plus medroxyprogesterone acetate 57 chemoradiation therapy 57 hematologic toxicity 57 titrated glipizide 57 peginterferon alfa 57 Celsentri Selzentry 57 Treatment Naive Patients 57 RAPTIVA 57 briakinumab 57 R rilonacept Injection 57 Hazard Ratio 57 mCRC patients 57 CYP#D# inhibitor 57 INVEGA ® 57 decitabine 57 beta 1a 57 OADs 57 cisplatin gemcitabine 57 baseline LDH 57 scores TNSS 57 CHOP chemotherapy 57 LMWH 57 vertebral fracture 57 ipsilateral stroke 57 Capecitabine 57 GOUT 57 severe renal impairment 57 DAS# CRP 57 systemic ALCL 57 receiving SIMPONI 57 evaluable patients 57 YMRS 57 PREZISTA ritonavir 57 tipranavir ritonavir 57 nondiabetic patients 57 leukopenia 57 psoriatic arthritis PsA 57 serum phosphorous 57 aPTT 57 ALT normalization 57 virologic responses 57 metformin monotherapy 57 aminotransferases 57 SUSTENNA TM 57 urate lowering therapy 57 PANSS scores 57 free survival PFS 57 rilpivirine 57 zoledronic acid 57 #mg/kg [002] 57 Severity MSCS score 57 pyridostigmine 57 FROVA 57 daunorubicin 57 cerebrovascular events 57 deep venous thromboses 57 liver enzymes ALT 57 tolvaptan 57 entecavir 57 peripheral sensory neuropathy 57 pamidronate 57 pegylated interferon alfa 2a 57 platelet reactivity 57 Durezol 57 relapsed refractory multiple myeloma 57 Taxus Stent 57 gemcitabine Gemzar 57 5FU 57 antiviral efficacy 57 HBeAg negative 57 refractory NSCLC 57 mesalamine granules 57 Pemetrexed 57 #Gy 57 Pegylated Liposomal Doxorubicin 57 postdose 57 CYPHER Stent 57 goserelin 57 febuxostat 57 salmeterol inhalation powder 57 pulmonary exacerbation 57 EDEMA3 trial 57 Bosentan 57 dasatinib Sprycel ® 57 HCV genotype 57 events AEs 57 active ankylosing spondylitis 57 achieved sustained virological 57 tipranavir 57 EDARBI 57 viral kinetics 57 systemic corticosteroid 57 Visual Analog Scale 57 ASCT 56 monotherapy 56 events MACE 56 bone marrow reticulin deposition 56 XIENCE V vs. 56 pegylated interferon alfa 2b 56 cyclophosphamide chemotherapy 56 prospectively stratified 56 locoregional disease 56 Timed Walk 56 neoadjuvant treatment 56 CDAI score 56 hypophosphatemia 56 x ULN 56 REVLIMID ® 56 H2RAs 56 apremilast 56 glucose lowering 56 receiving VICTRELIS 56 Copegus ribavirin 56 CLL SLL 56 heavily pretreated patients 56 SUTENT 56 ara C 56 #mg/m# [002] 56 Telbivudine 56 statin monotherapy 56 log# 56 docetaxel prednisone 56 virologically suppressed 56 golimumab CNTO 56 Lucentis monotherapy 56 demonstrated statistically significant 56 olanzapine quetiapine 56 dizziness nausea diarrhea 56 severe neutropenia 56 REMICADE monotherapy 56 mycophenolic acid 56 Scale cognitive subscale 56 ABC/3TC 56 blastic phase 56 spontaneous bowel movements 56 p = #.# [002] 56 forodesine 56 APTIVUS 56 inhalations twice 56 olanzapine risperidone 56 bendamustine 56 perioperatively 56 pooled comparator 56 postoperative chemotherapy 56 hemoglobin A1c levels 56 Budesonide foam crofelemer 56 sulfasalazine 56 EGFR mutation positive 56 UPDRS scores 56 Stent thrombosis 56 fasting plasma glucose 56 etanercept 56 randomized #:#:# 56 mL/min/#.# m2 56 anthracycline containing 56 pregabalin 56 WOMAC scores 56 quetiapine 56 oral diclofenac 56 Teriflunomide 56 peg interferon 56 oxycodone IR 56 del 5q MDS 56 COPD exacerbations 56 aspirin clopidogrel 56 ABVD 56 iniparib 56 metformin IR 56 mutated KRAS 56 teriparatide 56 inactive placebo 56 lamivudine monotherapy 56 PROCTOCORT ® Suppository Hydrocortisone 56 Apidra ® 56 infliximab therapy 56 FDA defined valvulopathy 56 HMG CoA reductase inhibitors 56 tumor regressions 56 virologic 56 recurrent ischemia 56 IOP lowering 56 mean baseline HbA1c 56 hematologic parameters 56 + PH# 56 Gemcitabine 56 Hb A1C 56 mg/m2 dose 56 androgen deprivation 56 oral antidiabetes 56 achieving PASI 56 baseline FEV 56 Partial Response 56 oral antidiabetic drugs 56 Capacity FVC 56 weekly CSBMs 56 inhaled iloprost 56 dose dexamethasone 56 HBeAg 56 pain palliation 56 undetectable virus HCV 56 tumor shrinkage 56 antiarrhythmic drug 56 plus GP IIb 56 parkinsonian symptoms 56 serum urate 56 FASLODEX 56 ejection fractions 56 gemcitabine chemotherapy 56 cilostazol 56 alanine aminotransferase 56 Median survival 56 creatinine ratio 56 TTF Therapy 56 valacyclovir 56 interferon gamma 1b 56 Fibromyalgia Impact Questionnaire 56 LEXIVA 56 plus glycoprotein IIb 56 IFN α 56 response CCyR 56 pyrazinamide 56 transaminases 56 transaminase elevations 56 PCWP 56 nonsignificant difference 56 Erythropoietic therapies may 56 HBeAg positive 56 stable angina pectoris 56 nasal symptom 56 subtrochanteric 56 comparator PI r 56 HCTZ 56 creatinine clearance 56 conjugated equine estrogen 56 ADAS Cog 56 refractory AML 56 lamivudine 56 olanzapine LAI 56 candesartan 56 Platinol ® cisplatin 56 inflammatory lesions 56 acute gout flares 56 Left Ventricular Ejection Fraction 56 Median progression 56 sitagliptin metformin 56 blood Phe 56 REMINYL ® 56 amisulpride 56 Pred Forte 56 NNRTI resistance 56 serum calcium levels 56 sirolimus eluting stent 56 lintuzumab SGN 56 receiving PEGINTRON 56 refractory CLL 56 PegIFN 56 VIRAMUNE 56 3TC lamivudine Epivir 56 % Confidence Interval 56 divalproex 56 CDAI 56 esomeprazole 56 DOXIL ® 56 remission induction 56 abciximab 56 PEGylated Fab fragment 56 rapid virologic response 56 hsCRP levels 56 oxcarbazepine 56 nilotinib 56 oral levofloxacin 56 plus octreotide LAR 56 galiximab 56 INTEGRILIN R 56 AUA Symptom Score 56 discontinuations 56 patients evaluable 56 enalapril 56 HBV DNA 56 leucopenia 56 NMIBC 56 HER2 expression 56 LIALDA 56 Viread Emtriva Sustiva 56 nab paclitaxel 56 Betaferon R 56 tumor necrosis 56 lanthanum carbonate 56 dose cohort 56 Disease Activity 56 COPAXONE ® 56 R entecavir 56 mg d 56 HOMA IR 56 NIHSS 56 induce orthostatic hypotension 56 Postoperatively 56 KRAS wild 56 epoetin beta 56 LANTUS R 56 MGd 56 dose regimens 56 Etanercept 56 FAMPYRA 56 Montgomery Åsberg Depression 56 Fludarabine 55 Lamictal XR 55 mg subcutaneously 55 FOSRENOL ® 55 mCRPC 55 Pegylated Interferon 55 atheroma volume 55 peginterferon alpha 2a 55 CI #.#-#.# [002] 55 mg dose 55 concomitant antibiotics 55 Operative mortality 55 coinfected 55 darunavir r 55 imipenem 55 PREZISTA r 55 amprenavir 55 CNV lesion 55 dosing cohorts 55 bosutinib 55 Febrile neutropenia 55 sotalol 55 vandetanib 55 thromboembolic complications 55 conventional DMARDs 55 microgram kg 55 flutamide 55 cinacalcet 55 oral vancomycin 55 dyslipidaemia 55 Gemzar ® 55 receiving immunosuppressive therapy 55 Tarceva TM 55 primary patency 55 mg subcutaneous 55 activated partial thromboplastin 55 seroprotection 55 R abatacept 55 stent thromboses 55 RECIST criteria 55 squamous histology 55 mcg mL 55 rizatriptan 55 mg doses 55 sitagliptin 55 melphalan prednisone 55 ARIXTRA 55 mg Lucentis 55 vidofludimus 55 generalized edema 55 aplindore 55 paroxetine sertraline 55 tapentadol IR 55 seropositivity 55 CANCIDAS 55 fluticasone 55 completely resected 55 Unified Parkinson Disease 55 IBS C 55 fluvastatin 55 hemodynamically significant 55 oral methylnaltrexone 55 olmesartan 55 eszopiclone 55 #mg ATC 55 dasatinib Sprycel 55 simvastatin ezetimibe 55 febrile neutropenia 55 PEG Interferon alfa 55 BEACOPP 55 mg Proellex 55 q8h 55 aromatase inhibitor therapy 55 ropivacaine 55 p = 55 STELARA 55 pioglitazone 55 glycosylated hemoglobin HbA1c 55 microbiologically evaluable 55 methotrexate therapy 55 Adefovir 55 viral suppression 55 evaluable 55 posttreatment 55 PSA nadir 55 Baseline characteristics 55 NNT = 55 ALT elevations 55 adjuvant tamoxifen 55 normal ULN 55 confidence interval #.#-#.# 55 Hepatotoxicity 55 mg administered orally 55 methotrexate 55 μg kg 55 p = .# [001] 55 Peginterferon alfa 2a 55 ziprasidone 55 multivariate adjustment 55 NLX P# 55 postoperatively 55 Irinotecan 55 NATRECOR R 55 metastatic GIST 55 carotid intima media 55 BPH Symptom Score 55 mg/# mg [001] 55 Femara letrozole 55 pruritus itching 55 donepezil 55 steroid dexamethasone 55 BARACLUDE r 55 oxymorphone ER 55 echocardiographic parameters 55 Cladribine tablets 55 treatment naive genotype 55 Alzheimer Disease Assessment 55 LHRH analogues 55 fatigue asthenia 55 cabazitaxel 55 mmHg p = 55 TRIZIVIR 55 T2 lesion volume 55 fluticasone propionate 55 CTEPH 55 tamoxifen Nolvadex ® 55 anemia neutropenia 55 non valvular atrial 55 boosted protease inhibitor 55 Cutaneous T 55 PANSS 55 COMBIVIR